Novo Nordisk's sales increased by 31% to DKK 232.26 billion, and Net profit increased by 51% to DKK 83.68 billion in 2023. Analysts polled by Visible Alpha were expecting 82.55 billion kroner in net profit, while sales were estimated at 229.36 billion kroner.
诺和诺德的销售额增长了31％，达到2322.6亿丹麦克朗，2023年净利润增长了51％，达到836.8亿丹麦克朗。Visible Alpha调查的分析师预计净利润为825.5亿克朗，而销售额估计为2293.6亿克朗。
Sales within Diabetes and Obesity care increased by 38% in Danish kroner to DKK 215.1 billion (42% at constant exchange rates), mainly driven by GLP-1 diabetes sales growth of 48% in Danish kroner (52% at CER) and Obesity care growing by 147% in Danish Kroner to DKK 41.6 billion (154% at CER). Rare disease sales decreased by 16% measured in Danish kroner (15% at CER) reflecting a reduction in manufacturing output.
糖尿病和肥胖症护理领域的销售额以丹麦克朗计算增长了38％，达到2151亿丹麦克朗（按固定汇率计算为42％），这主要是由以丹麦克朗计算的 GLP-1 糖尿病销售额增长48％（按恒定汇率计算为52％），以及肥胖护理以丹麦克朗计算增长147％，达到416亿丹麦克朗（按恒定汇率计算为154％）。以丹麦克朗计算，罕见病销售额下降了16％（按CER计算为15％），这反映了制造业产出的下降。
For 2024, the company expects 18% to 26% sales growth and 21% to 29% operating profit growth at constant exchange rates. The increase in sales and operating profit in Danish kroner is expected to be 1 percentage point and 2 percentage points lower than at constant exchange rates, respectively.
该公司预计，按固定汇率计算，2024年的销售额将增长18％至26％，营业利润增长21％至29％。以丹麦克朗计算，销售额和营业利润的增长预计将分别比固定汇率低1个百分点和2个百分点。